Mouse models ofPIK3CAmutations: one mutation initiates heterogeneous mammary tumors

PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients

(2012) FR Mangone et al.   Clinics

Conditional activation of Pik3ca H1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations

(2012) W Yuan et al.   ONCOGENE

Physiological Levels of Pik3caH1047R Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors

(2012) Anjali Tikoo et al.   PLoS One

Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes

(2011) Sandrine Boyault et al.   BREAST CANCER RESEARCH AND TREATMENT

Cooperation between Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation

(2011) J. R. Adams et al.   CANCER RESEARCH

Luminal Expression of PIK3CA Mutant H1047R in the Mammary Gland Induces Heterogeneous Tumors

(2011) D. S. Meyer et al.   CANCER RESEARCH

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms

(2011) Pixu Liu et al.   NATURE MEDICINE

Choosing a Mouse Model: Experimental Biology in Context--The Utility and Limitations of Mouse Models of Breast Cancer

(2011) A. D. Borowsky   Cold Spring Harbor Perspectives in Biology

PIK3CA Mutations in In situ and Invasive Breast Carcinomas

(2010) A. Miron et al.   CANCER RESEARCH

PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer

(2010) J. Dupont Jensen et al.   CLINICAL CANCER RESEARCH

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

(2009) Y. Kataoka et al.   ANNALS OF ONCOLOGY

Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma

(2009) Jennifer Dunlap et al.   BREAST CANCER RESEARCH AND TREATMENT

Identification of Novel Gene Amplifications in Breast Cancer and Coexistence of Gene Amplification with an Activating Mutation of PIK3CA

(2009) M. Kadota et al.   CANCER RESEARCH

PIK3CA Mutation Associates with Improved Outcome in Breast Cancer

(2009) K. Kalinsky et al.   CLINICAL CANCER RESEARCH

Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells

(2009) T. W. Miller et al.   CLINICAL CANCER RESEARCH

PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast

(2009) Hua Li et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients

(2008) Yuen-Liang Lai et al.   ANNALS OF SURGICAL ONCOLOGY

Activation of Phosphatidylinositol 3-Kinase by Membrane Localization of p110  Predisposes Mammary Glands to Neoplastic Transformation

(2008) O. Renner et al.   CANCER RESEARCH

Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis

(2008) N. Dourdin et al.   CANCER RESEARCH

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2008) P. J.A. Eichhorn et al.   CANCER RESEARCH

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

Class I PI3K in oncogenic cellular transformation

(2008) L Zhao et al.   ONCOGENE

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE